Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In Process Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

10x Genomics (TXG) Shares Issued (2018 - 2026)

10x Genomics' Shares Issued history spans 8 years, with the latest figure at $2.2 million for Q4 2025.

On a quarterly basis, Shares Issued fell 50.37% to $2.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.8 million, a 37.67% decrease, with the full-year FY2025 number at $6.8 million, down 37.67% from a year prior.
Shares Issued hit $2.2 million in Q4 2025 for 10x Genomics, up from $617000.0 in the prior quarter.
Over the last five years, Shares Issued for TXG hit a ceiling of $16.2 million in Q2 2021 and a floor of $156000.0 in Q3 2024.
Historically, Shares Issued has averaged $4.9 million across 5 years, with a median of $4.6 million in 2024.
Biggest five-year swings in Shares Issued: plummeted 98.58% in 2021 and later soared 295.51% in 2025.
Tracing TXG's Shares Issued over 5 years: stood at $8.9 million in 2021, then crashed by 43.83% to $5.0 million in 2022, then grew by 12.24% to $5.6 million in 2023, then decreased by 19.53% to $4.5 million in 2024, then plummeted by 50.37% to $2.2 million in 2025.
Business Quant data shows Shares Issued for TXG at $2.2 million in Q4 2025, $617000.0 in Q3 2025, and $3.5 million in Q2 2025.